Nonvalvüler Atrial Fibrilasyon Nedeni ile Yeni Oral Antikoagülan veya Varfarin Kullanan Covid-19 Tanılı Hastaların D-dimer Düzeyleri ile Normal Sinüs Ritmindeki Covid-19 Tanılı Hastaların D-dimer Düzeylerinin Karşılaştırılması

GİRİŞ ve AMAÇ: Koronavirüs hastalığı-19 (Covid-19), eşlik eden kalp hastalığı olan hastalarda kötü prognoza sahiptir ve yüksek mortalite ve tromboembolik olay oranlarına sahiptir.Bu çalışmanın amacı; Covid-19 lu nonvalvüler atrial fibrilasyon (AF) nedeni ile yeni oral antikoagülan veya varfarin kullanan hastaların D-dimer düzeyleri ile Covid-19'lu normal sinüs ritmindeki (NSR) hastaların D-dimer düzeylerinin karşılaştırılmasıdır. YÖNTEM ve GEREÇLER: Bu çalışma retrospektif gözlemsel vaka-kontrol çalışmasıdır. Laboratuvar onaylı PCR pozitif Covid19'lu hastalar ve PCR negatif fakat temas öyküsü, laboratuvar ve bilgisayarlı tomografi bulguları olan yüksek klinik şüphesi olan Covid-19'lu 50 (%0.11) si AF li ve 53 (%0.12) ü NSR olan toplam 103 ardışık hasta çalışmaya alındı. Benzer yaş ve cinsiyetteki uygun hastalar AF ve NSR grubu olarak ikiye bölündü. Hastaneye başvurudaki ve kontroldeki D-dimer düzeyleri karşılaştırıldı. BULGULAR: Hastaneye kabulde, AF ve NSR grubundaki ortalama D-dimer seviyeleri sırasıyla 2.07 ± 4.41 µg/ml ve 1.89 ± 3.87 µg/ml idi: iki grup arasında istatistiksel olarak fark yoktu (p=0.345). Tedavinin beşinci gününde AF ve NSR grubundaki ortalama kontrol D-dimer seviyeleri sırasıyla 2.18 ± 3.31 µg/ml ve 2.06 ± 3.44 µg/ml idi: iki grup arasında istatistiksel olarak fark yoktu (p=0.814). İki grup arasında mortalite analizi yapıldığında hastaneye kabulde yaşayan Covid-19'lu hastaların ortalama Ddimer seviyeleri 1.40± 3.30 µg/ml iken yaşamayan Covid-19'lu hastaların D-dimer seviyeleri 4.41± 6.30 µg/ml idi: iki grup arasında belirgin fark vardı ve bu fark istatistiksel olarak anlamlı idi p= 0.020. TARTIŞMA ve SONUÇ: Nonvalvüler AF nedeniyle NOAC veya varfarin kullanan hastalarda Covid-19 sürecinde tromboembolizm oranlarında ve D-dimer düzeylerinde artış izlenmedi. Literatürde, Covid-19 hastalarında AF'li ve NSR'de olanlar karşılaştırıldığında D-dimer düzeylerini ve tromboembolik oranlarını karşılaştıran çalışmaya rastlanmadı.

Comparison between D-dimer Levels of Covid-19 Patients Using New Oral Anticoagulants or Warfarin Due to Nonvalvular Atrial Fibrillation and D-dimer Levels of Covid-19 Patients with Normal Sinus Rhythm

INTRODUCTION: Coronavirus Disease 2019 (Covid-19) patients with concomitant cardiac diseases have poor prognosis and have high mortality and thromboembolic event rates. The aim of this study is to compare D-dimer levels of Covid-19 patients using new oral anticoagulants (NOAC) or warfarin due to nonvalvular atrial fibrillation (AF) and Covid-19 patients with normal sinus rhythm (NSR). METHODS: It is an observational retrospective case-control study. 103 consecutive patients, 50 (0.11%) AF and 53 (0.12%) NSR with laboratory confirmed Covid-19 PCR positivity and patients who are PCR negative but have a high clinical suspicion of Covid-19 due to their contact history, laboratory and computed tomography findings were enrolled. The eligible patients of similar age and gender were divided into AF and NSR groups. Admission and control D-dimer levels were compared. RESULTS: On admission mean D-dimer levels were 2.07 ± 4.41 µg/ml and 1.89 ± 3.87 µg/ml in the AF and NSR group, respectively: between two groups no statistically significant difference was found (p=0.345). Control D-dimer levels on the fifth day of treatment were 2.18 ± 3.31 µg/ml and 2.06 ± 3.44 µg/ml in the AF and NSR group, respectively: between two groups no statistically significant difference was found (p=0.814). DISCUSSION and CONCLUSION: In patients using NOAC or warfarin due to nonvalvular AF, no increase in thromboembolism event rates and elevated D-dimer levels were observed during the Covid-19 process. There was no study in the literatüre that compared D-dimer levels and thromboembolic event rates of AF and NSR group with Covid-19 patients.

PDF

___

1. Layton DS, Choudhary A, Bean AGD. Breaking the chain of zoonoses through biosecurity in livestock. Vaccine. 2017;35:5967-73.
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China Nature. 2020;579:265-9.
3. Corovavirus Disease (Covid-19), World Health Organization Situation Report on September 6, 2020. Available from: https://www.who.int/docs/defaultsource/coronaviruse/situationreports/20200907-weekly-epi-update4.pdf?sfvrsn=f5f607ee_2
4. Zhang L, Long Y, Xiao H, Yang J, Toulon P, Zhang Z. Use of D-dimer in oral anticoagulation therapy. International journal of laboratory hematology. 2018;40:503-7.
5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020;18:844-7.
6. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41:1858.
7. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.J Thromb Haemost. 2020;18:1421-4.
8. Tang N, Bai H, Chen X, Gong J, LiD, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. 2020;18:1094–9.
9. WHO Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020. Available from: https://www.who.int/publications/i/item/clini cal-management-of-covid-19
10. Republic of Turkey Ministry of Health Covid-19 directory, science board study, 12 April 2020, Ankara. Available from: https://www.ekmud.org.tr/files/uploads/files/ COVID-19_Rehberi-6.pdf
11. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, VanderHeide RS. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series. April 10, 2020.medRxiv. Availablefrom: https://doi.org/10.1101/2020.04.06.20050 575
12. Richard C. Becker. COVID-19 update: Covid-19 associated coagulopathy. J Thromb Thrombolysis. 2020;50:54-67. 13. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
14. Guo L, Rondina MT. The era of thromboinflammation: platelets are dynamics sensors and effector cells during infectious diseases. Front Immunol 2019;10:2204
15. Sharma GK, Talbot IC. Pulmonary megakaryocytes: "missing link" between cardiovascular and respiratory disease? J ClinPathol.1986;39:969–76.
16. Becker RC. Covid-19 treatment update: follow the scientific evidence. J Thromb Thrombolysis. 2020;50:43-53.
17. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
20. ZhangL, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid19. J Thromb Haemost. 2020;18:1324-9.
21. David Fitzmaurice. Atrial fibrillation and coagulation: who and when? Blood Reviews. 2009; 23:241-4.
22. Roncon L, Zuin M. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354.
23. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020;126:108961.